Birchview Capital LP Takes $346,000 Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

Birchview Capital LP purchased a new stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 8,000 shares of the company's stock, valued at approximately $346,000.

A number of other large investors also recently bought and sold shares of SRRK. Barclays PLC boosted its holdings in Scholar Rock by 103.4% during the third quarter. Barclays PLC now owns 165,449 shares of the company's stock worth $1,324,000 after buying an additional 84,118 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Scholar Rock by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company's stock valued at $12,361,000 after acquiring an additional 120,489 shares during the period. Vanguard Group Inc. increased its stake in shares of Scholar Rock by 17.6% in the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after purchasing an additional 708,817 shares in the last quarter. Principal Financial Group Inc. acquired a new position in Scholar Rock in the 4th quarter worth about $274,000. Finally, Rhumbline Advisers boosted its position in Scholar Rock by 13.2% during the fourth quarter. Rhumbline Advisers now owns 113,261 shares of the company's stock worth $4,895,000 after purchasing an additional 13,247 shares in the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Trading Down 4.6 %

SRRK stock opened at $32.81 on Friday. The business's 50-day moving average is $32.77 and its 200 day moving average is $35.60. Scholar Rock Holding Co. has a 12-month low of $6.76 and a 12-month high of $46.98. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of -13.96 and a beta of 0.56. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63.

Insider Transactions at Scholar Rock

In other news, insider Tracey Sacco sold 6,500 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $33.08, for a total value of $215,020.00. Following the completion of the sale, the insider now directly owns 71,750 shares in the company, valued at $2,373,490. This represents a 8.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Edward H. Myles sold 7,809 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total transaction of $287,605.47. Following the transaction, the chief financial officer now owns 140,740 shares in the company, valued at $5,183,454.20. The trade was a 5.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 250,231 shares of company stock valued at $9,056,086 over the last ninety days. Insiders own 13.30% of the company's stock.

Analysts Set New Price Targets

Separately, Wedbush reaffirmed an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a research note on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $42.67.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

Want to see what other hedge funds are holding SRRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.